the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients

Summary

the study to investigate the efficacy of empagiflozin in pediatric heart failure

Eligibility

Inclusion Criteria:

* • Pediatrics (aged 1months-18 years)

  * Confirmed HF diagnosis:

HF will be defined by reduced ventricular systolic function (left ventricular ejection fraction by echocardiography) or impaired ventricular filling (pulmonary capillary wedge pressure \> 18 mmHg measured directly and/or the ratio of early diastolic mitral inflow velocity(E) to early diastolic mitral annular velocity (e')( E/e'\>14 by echocardiography) with clinical features of congestion and/or low cardiac output.

• Class III or IV of ROSS classification or BNP level more than 300 pg/mL

Exclusion Criteria:

* • Pediatric with chronic kidney failure

  * Avoid initiating empagliflozin in patients with concurrent urinary tract infection (UTI).
  * patients with eGFR \<60 mL/minute/1.73 m2 will be excluded.
  * Patients with contraindication to empagliflozin usage which include

    * eGFR \<30 mL/minute/1.73 m2
    * Hypersensitivity (eg, angioedema) to empagliflozin

Conditions2

Interventions2

Related trials

• Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus — Mayo Clinic
• A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial). — European Foundation for Study of Chronic Liver Failure
• Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure — Beijing 302 Hospital
• Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure — Institute of Liver and Biliary Sciences, India

Browse More Trials